南美超级胎牛血清999尝鲜特惠
转染试剂低至5折
基质胶阶梯特惠
积分商城,好礼送不停
南美超级胎牛血清999尝鲜特惠
转染试剂低至5折
基质胶阶梯特惠
积分商城,好礼送不停

一种响应性仿生纳米佐剂,可诱导焦亡并控制雷西替莫德释放,以增强肿瘤光免疫疗法效果

A Responsive Biomimetic Nanoagonist for Pyroptosis Induction and Controlled Resiquimod Release to Enhance Tumor Photoimmunotherapy

Wenfeng Zeng, Juntao Xie, Yeqi Shen, Yiqiu Fu, Xinyi Wang, Wen Li, Qingyun Liu, Hanyue Li, Jiahui Cao, Yongkang Yu, Jisheng Xiao, Meitong Ou, Lin Mei

Journal:Acta Biomaterialia

IF:10.4

DOI:10.1016/j.actbio.2026.09.019

PMID:42727871

Published:2026-09-11

research field:肿瘤微环境药物递送系统光动力治疗先天免疫癌症免疫治疗纳米医学

Abstract

Immune suppression of tumor microenvironment (TME) limits the effectiveness of the immune therapy. Although inducing tumor cell pyroptosis and activating innate immunity are effective strategies to reverse this microenvironment, current methods are often hindered by non-targeted toxicity and the inability to precisely control drug release. To address these challenges, we synthesized an ROS-responsive R848 prodrug with a maleimide structure. Then, Hemin was coupled to bovine serum albumin (BSA) and the disulfide bonds within the BSA molecule were reduced, exposing free thiol groups. The R848 prodrug was then conjugated to the thiol groups, and the photosensitizer Ce6 was loaded, allowing self-assembly into the HBSA@CR nanoagonist. This strategy not only achieved a higher drug loading capacity than traditional albumin nanoparticles, but also retained the biocompatibility of natural albumin and the advantages of receptor-mediated cellular uptake. HBSA@CR can be activated by 660 nm laser irradiation to efficiently generate ROS through photodynamic and enzymatic catalysis. In vitro experiments show that this nanoparticle can efficiently kill tumor cells, induce pyroptosis through the Caspase-3/GSDME pathway and trigger the release of R848. In tumor-bearing mouse models, HBSA@CR effectively inhibited primary tumor growth and lung metastasis, and reprogrammed the immunosuppressive TME. In a tumor rechallenge model, this strategy prevented tumor recurrence and conferred long-lasting immunological memory. Moreover, when used in combination with the immune checkpoint inhibitor αPD-L1, this nanoparticle exhibits synergistic therapeutic effects. The designed nanoagonist offers a biomimetic platform for combined photo-immunotherapy, which achieves controlled R848 release while inducing tumor cell pyroptosis, reprogramming the immunosuppressive TME, and eliciting durable antitumor immunological memory. Statement of Significance The immunosuppressive tumor microenvironment is one

本文使用的Yeasen产品

购物车
客服
转染试用